{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:34:27Z","timestamp":1790159667401,"version":"4.1.0"},"publisher-location":"Cham","reference-count":32,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030109486","type":"print"},{"value":"9783030109493","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/164_2018_167","type":"book-chapter","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T12:31:26Z","timestamp":1536323486000},"page":"325-355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Other Antidepressants"],"prefix":"10.1007","author":[{"given":"T. E.","family":"Schwasinger-Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Macaluso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,8]]},"reference":[{"key":"167_CR1","doi-asserted-by":"publisher","unstructured":"Alam A, Voronovich Z, Carley JA (2013) A review of therapeutic uses of mirtazapine in psychiatric and medical conditions. Prim Care Companion CNS Disord 15(5). pii: PCC.13r01525. doi: https:\/\/doi.org\/10.4088\/PCC.13r01525","DOI":"10.4088\/PCC.13r01525"},{"key":"167_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2165\/00003495-198121060-00001","volume":"21","author":"RN Brogden","year":"1981","unstructured":"Brogden RN, Heel RC, Speight TM et al (1981) Drugs 21:401 https:\/\/doi.org\/10.2165\/00003495-198121060-00001","journal-title":"Drugs"},{"key":"167_CR3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-3565(25)32266-4","volume":"215","author":"BR Cooper","year":"1980","unstructured":"Cooper BR, Hester TJ, Maxwell RA (1980) Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther 215:127\u2013134","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"167_CR4","first-page":"28","volume":"37","author":"M Cruz","year":"2012","unstructured":"Cruz M (2012) Vilazodone HCL: a serotonin partial agonist and reuptake inhibitor for the treatment of major depressive disorder. P T 37(1):28\u201331","journal-title":"P T"},{"issue":"1","key":"167_CR5","first-page":"36","volume":"40","author":"A D\u2019Agostino","year":"2015","unstructured":"D\u2019Agostino A, English C, Rey J (2015) Vortioxetine (Brintellix): a new serotonergic antidepressant. P T 40(1):36\u201340","journal-title":"P T"},{"issue":"S1","key":"167_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2165\/00023210-199500041-00006","volume":"4","author":"T Boer De","year":"1995","unstructured":"De Boer T, Ruigt GSF (1995) The selective alpha2-adrenoceptor antagonist mirtazapine (Org 3770) enhances noradrenergic and 5HT1A mediated serotonergic neurotransmission. CNS Drugs 4(S1):29\u201338","journal-title":"CNS Drugs"},{"issue":"12","key":"167_CR7","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s40263-012-0010-5","volume":"26","author":"A Fagiolini","year":"2012","unstructured":"Fagiolini A, Comandini A, Dell\u2019Osso MC, Kasper S (2012) Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs 26(12):1033\u20131049. https:\/\/doi.org\/10.1007\/s40263-012-0010-5","journal-title":"CNS Drugs"},{"issue":"3","key":"167_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4088\/PCC.v07n0305","volume":"7","author":"M Fava","year":"2005","unstructured":"Fava M, Rush AJ, Thase ME et al (2005) 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 7(3):106\u2013113.v","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"167_CR9","unstructured":"Feighner JP, Boyer WF (1988) Overview of USA controlled trials of trazodone in clinical depression. Psychopharmacology (Berl) 95 Suppl:S50\u2013S53"},{"issue":"5","key":"167_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/j.1875-9114.1982.tb03193.x","volume":"2","author":"A Georgotas","year":"1982","unstructured":"Georgotas A, Forsell T, Mann J, Kim M, Gershon S (1982) Trazodone hydrochloride: a wide spectrum antidepressant with a unique pharmacological profile. A review of tis neurochemical effects, pharmacology, clinical efficacy, and toxicology. Pharmacotherapy 2(5):255\u2013263","journal-title":"Pharmacotherapy"},{"key":"167_CR11","unstructured":"GlaxoSmithKline (2009) FDA prescribing information for bupropion hydrochloride. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/018644s039s040.pdf"},{"key":"167_CR12","unstructured":"GlaxoSmithKline (2017) Medication guide for bupropion. FDA approved. https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Wellbutrin_Tablets\/pdf\/WELLBUTRIN-TABLETS-PI-MG.PDF"},{"issue":"Suppl 4","key":"167_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/00004850-199512004-00003","volume":"10","author":"N Haddjeri","year":"1995","unstructured":"Haddjeri N, Blier P, de Montigny C (1995) Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmacol 10(Suppl 4):11\u201317","journal-title":"Int Clin Psychopharmacol"},{"key":"167_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/CE.S54075","volume":"10","author":"DJ Hellerstein","year":"2015","unstructured":"Hellerstein DJ, Flaxer J (2015) Vilazodone for the treatment of major depressive disorder: an evidence based review of its place in therapy. Core Evid 10:49\u201362","journal-title":"Core Evid"},{"issue":"1","key":"167_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/00004714-200002000-00019","volume":"20","author":"G Laakmann","year":"2000","unstructured":"Laakmann G, Sch\u00fcle C, Baghai T, Waldvogel E, Bidlingmaier M, Strasburger C (2000) Mirtazapine: an inhibitor of cortisol secretion that does not influence growth hormone and prolactin secretion. J Clin Psychopharmacol 20(1):101\u2013103","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"167_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/nedt.1.1.59.52296","volume":"1","author":"F Lavergne","year":"2005","unstructured":"Lavergne F, Berlin I, Gamma A, Stassen H, Angst J (2005) Onset of improvement and response to mirtazapine in depression: a multicenter naturalistic study of 4771 patients. Neuropsychiatr Dis Treat 1(1):59\u201368","journal-title":"Neuropsychiatr Dis Treat"},{"key":"167_CR17","unstructured":"Mead Johnson (2017) Trazadone hydrochloride package insert. http:\/\/www.mentalmeds.org\/prescription_meds\/Desyrel.pdf"},{"key":"167_CR18","unstructured":"Merck (2012) Mirtazapine tablet insert 76621. FDA approved. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/020415s019,021208s010lbl.pdf"},{"key":"167_CR19","unstructured":"Merck (2017) Medication guide for mirtazapine. FDA approved. http:\/\/www.merck.com\/product\/usa\/pi_circulars\/r\/remeron\/remeron_tablets_pi.pdf"},{"key":"167_CR20","unstructured":"Pierz KA, Thase ME (2014) A review of vilazodone, serotonin, and major depressive disorder. Prim Care Companion CND Discord 16(1). pii: PCC.13r01554"},{"key":"167_CR21","unstructured":"Pragma Pharmaceuticals (2017) Prescribing information for trazodone hydrochloride. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/018207s032lbl.pdf"},{"key":"167_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/978-3-642-18500-7_10","volume-title":"Antidepressants: Past, Present and Future","author":"S. H. Preskorn","year":"2004","unstructured":"Preskorn S, Ross R (2004) Antidepressants: past, present and future. Other antidepressants, vol 157. Springer, Berlin, pp 263\u2013324"},{"issue":"3","key":"167_CR23","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4088\/JCP.08m04637","volume":"70","author":"K Rickels","year":"2009","unstructured":"Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR (2009) Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double blind, placebo controlled trial. J Clin Psychiatry 70(3):326\u2013333","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"167_CR24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1517\/17460441.2016.1160051","volume":"11","author":"Z Sahli","year":"2016","unstructured":"Sahli Z, Banerjee P, Tarazi F (2016) The preclinical and clinical effects of vilazodone for the treatment of major depressive disorder. Expert Opin Drug Discov 11(5):515\u2013523","journal-title":"Expert Opin Drug Discov"},{"key":"167_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","volume":"145","author":"C Sanchez","year":"2015","unstructured":"Sanchez C, Asin K, Artigas F (2015) Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther 145:43\u201357","journal-title":"Pharmacol Ther"},{"issue":"1","key":"167_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00213-002-1148-5","volume":"163","author":"C Sch\u00fcle","year":"2002","unstructured":"Sch\u00fcle C, Baghai T, Goy J, Bidlingmaier M, Strasburger C, Laakmann G (2002) The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology (Berl) 163(1):95\u2013101","journal-title":"Psychopharmacology (Berl)"},{"issue":"10","key":"167_CR27","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1017\/S1092852900024020","volume":"14","author":"SM Stahl","year":"2009","unstructured":"Stahl SM (2009) Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 14(10):536\u2013546","journal-title":"CNS Spectr"},{"key":"167_CR28","unstructured":"Takeda Pharmaceuticals (2018) Vortioxetine package insert. https:\/\/general.takedapharm.com\/TRINTELLIXPI"},{"issue":"8","key":"167_CR29","doi-asserted-by":"publisher","first-page":"974","DOI":"10.4088\/JCP.v66n0803","volume":"66","author":"ME Thase","year":"2005","unstructured":"Thase ME, Haight BR, Richard N et al (2005) Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 66(8):974\u2013981","journal-title":"J Clin Psychiatry"},{"key":"167_CR30","unstructured":"Trovis (2011) Vilazodone hydrochloride prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022567s000lbl.pdf"},{"key":"167_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4068\/cmj.2016.52.2.91","volume":"52","author":"S Wang","year":"2016","unstructured":"Wang S, Han C, Lee S, Patkar A, Masand P, Pae C (2016) Vilazodone for the treatment of depression: an update. Chonnam Med J 52:91\u2013100","journal-title":"Chonnam Med J"},{"issue":"9","key":"167_CR32","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S0006-3223(01)01317-8","volume":"51","author":"KL Weihs","year":"2002","unstructured":"Weihs KL, Houser TL, Batey SR, Ascher JA, Bolden-Watson C, Donahue RM, Metz A (2002) Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry 51(9):753\u2013761","journal-title":"Biol Psychiatry"}],"container-title":["Handbook of Experimental Pharmacology","Antidepressants"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2018_167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T23:52:00Z","timestamp":1751845920000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/164_2018_167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9783030109486","9783030109493"],"references-count":32,"URL":"https:\/\/doi.org\/10.1007\/164_2018_167","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"8 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}